Vertex Pharmaceuticals (VRTX) TD Cowen 46th Annual Health Care Conference summary

Company overview and strategic direction

• Leadership in cystic fibrosis (CF) continues, with expansion into heme, pain, and emerging renal verticals, supported by a robust R&D pipeline with five pivotal programs and several in phase II development.

• Diversification strategy initiated over a decade ago targets diseases with high unmet need, validated biology, and efficient regulatory pathways, aiming for a diversified pipeline and revenue base.

• Strong balance sheet enables increased stock buybacks and supports ongoing innovation, both internally and through external partnerships.

• Focus remains on methodical, disease-first R&D, leveraging multiple modalities and external innovation to address 12–24 diseases of interest.

Renal franchise and pipeline updates

• Pove in IgAN is on track for interim phase III data and regulatory submission in the first half of the year, with breakthrough designation and rolling FDA review underway.

• Phase II RUBY-3 data showed increasing proteinuria reduction over time, with phase III RAINIER designed similarly but placebo-controlled.

• Safety focus is on infection risk due to B cell modulation, with phase II data guiding expectations for benefit/risk.

• Pove offers once-monthly, low-volume, auto-injector dosing, and potential for multiple renal indications, positioning it as a differentiated therapy.

Additional pipeline highlights

• Inaxaplin for APOL1-mediated kidney disease (AMKD) is in phase III, with interim results expected late this year or early next; positive results could lead to accelerated US approval.

• AMPLITUDE and AMPLIFIED studies are designed to clarify efficacy in pure AMKD and in patients with comorbidities like diabetes, informing future development steps.